Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphoma.

Jain N, Hartert K, Tadros S, Fiskus W, Havranek O, Ma MCJ, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu CL, Gentles AJ, Hartmann E, Kridel R, Smedby KE, Juliusson G, Rosenquist R, Gascoyne RD, Rosenwald A, Giancotti F, Neelapu SS, Westin J, Vose JM, Lunning MA, Greiner T, Rodig S, Iqbal J, Alizadeh AA, Davis RE, Bhalla K, Green MR.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaav5599. doi: 10.1126/scitranslmed.aav5599.

2.

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.

Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
31200358
3.

Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma.

Dhakal P, Chen B, Giri S, Vose JM, Armitage JO, Bhatt VR.

Future Oncol. 2019 Jun;15(18):2113-2124. doi: 10.2217/fon-2018-0596. Epub 2019 May 30.

PMID:
31144521
4.

Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.

Kallam A, Vose JM.

Oncology (Williston Park). 2019 May 14;33(5):192-8.

5.

ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.

Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, Tilly H, Jais JP, Savage KJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.213512. doi: 10.3324/haematol.2018.213512. [Epub ahead of print]

6.

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR.

Leuk Lymphoma. 2019 Sep;60(9):2255-2263. doi: 10.1080/10428194.2019.1574006. Epub 2019 Mar 8.

PMID:
30848966
7.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
8.

Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.

J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7.

PMID:
30615550
9.

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM.

Br J Haematol. 2019 Mar;184(5):744-752. doi: 10.1111/bjh.15702. Epub 2018 Dec 5.

PMID:
30520026
10.

A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib.

Chaturvedi NK, Hatch ND, Sutton GL, Kling M, Vose JM, Joshi SS.

Leuk Lymphoma. 2019 May;60(5):1214-1223. doi: 10.1080/10428194.2018.1520986. Epub 2018 Nov 14.

PMID:
30424705
11.

Assessment of hydrologic vulnerability to urbanization and climate change in a rapidly changing watershed in the Southeast U.S.

Suttles KM, Singh NK, Vose JM, Martin KL, Emanuel RE, Coulston JW, Saia SM, Crump MT.

Sci Total Environ. 2018 Dec 15;645:806-816. doi: 10.1016/j.scitotenv.2018.06.287. Epub 2018 Jul 24.

PMID:
30032080
12.

Terra incognita: The unknown risks to environmental quality posed by the spatial distribution and abundance of concentrated animal feeding operations.

Martin KL, Emanuel RE, Vose JM.

Sci Total Environ. 2018 Nov 15;642:887-893. doi: 10.1016/j.scitotenv.2018.06.072. Epub 2018 Jun 18.

PMID:
29929140
13.

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.

Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME, Horwitz S, Kim WS, Shustov A, Foss FM, Nagler A, Carson K, Pinter-Brown LC, Montoto S, Spina M, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Gabus R, Vose JM, Advani RH; T cell Project Network.

Br J Haematol. 2018 Jun;181(6):760-769. doi: 10.1111/bjh.15258. Epub 2018 Apr 19.

14.

Peripheral T-cell lymphoma: novel backbone.

Vose JM.

Blood. 2018 Jan 25;131(4):375-376. doi: 10.1182/blood-2017-11-817734. No abstract available.

PMID:
29371206
15.

Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.

Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.

Blood Adv. 2017 Dec 11;1(26):2600-2609. doi: 10.1182/bloodadvances.2017009472. eCollection 2017 Dec 12.

16.

Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement.

Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM.

J Clin Oncol. 2018 Feb 20;36(6):617-623. doi: 10.1200/JCO.2017.75.8193. Epub 2017 Dec 13. No abstract available.

PMID:
29236570
17.

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, Moskowitz CH, Fenton K, Ogden CA, Taft D, Zhang Q, Kato K, Campbell M, Advani RH.

Blood. 2018 Mar 15;131(11):1183-1194. doi: 10.1182/blood-2017-10-811224. Epub 2017 Dec 11.

18.

Follicular large cleaved cell (centrocytic) lymphoma: an unrecognized variant of follicular lymphoma.

El Behery R, Laurini JA, Weisenburger DD, Smith LM, Dave BJ, Yuan J, Fu K, Chan WC, Nathwani BN, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Greiner TC, Aoun P.

Hum Pathol. 2018 Feb;72:180-190. doi: 10.1016/j.humpath.2017.11.002. Epub 2017 Nov 21.

PMID:
29170017
19.

Learning From Our Patients.

Vose JM, Hayes D.

JCO Clin Cancer Inform. 2017 Nov;1:1-3. doi: 10.1200/CCI.16.00070. No abstract available.

20.

Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.

Yuan J, Greiner TC, Fu K, Smith LM, Aoun P, Chan WC, Bierman PJ, Bociek RG, Vose JM, Armitage JO, Weisenburger DD.

Clin Lymphoma Myeloma Leuk. 2017 Aug;17(8):488-497.e2. doi: 10.1016/j.clml.2017.06.006. Epub 2017 Jun 16.

PMID:
28842137
21.

Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study.

Giri S, Bhatt VR, Verma V, Pathak R, Bociek RG, Vose JM, Armitage JO.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):569-574. doi: 10.1016/j.clml.2017.06.028. Epub 2017 Jun 24.

PMID:
28709798
22.

Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2017 Aug;92(8):806-813. doi: 10.1002/ajh.24797. Review. Erratum in: Am J Hematol. 2018 May;93(5):E134.

23.

Challenges in Opening and Enrolling Patients in Clinical Trials.

Vose JM, Chuk MK, Giles F.

Am Soc Clin Oncol Educ Book. 2017;37:139-143. doi: 10.14694/EDBK_179807. Review.

PMID:
28561725
24.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

25.

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.

Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H.

J Natl Compr Canc Netw. 2017 Mar;15(3):293-311.

PMID:
28275031
26.

Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.

Lunning MA, Vose JM.

Blood. 2017 Mar 2;129(9):1095-1102. doi: 10.1182/blood-2016-09-692541. Epub 2017 Jan 23. Review.

PMID:
28115369
27.

Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas.

Bi C, Zhang X, Lu T, Zhang X, Wang X, Meng B, Zhang H, Wang P, Vose JM, Chan WC, McKeithan TW, Fu K.

Haematologica. 2017 Apr;102(4):755-764. doi: 10.3324/haematol.2016.159160. Epub 2017 Jan 19.

28.

Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia.

Khanal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, Maness LJ, Lunning MA, Gundabolu K, Bhatt VR.

Am J Hematol. 2016 Nov;91(11):E468-E472. doi: 10.1002/ajh.24526. Epub 2016 Aug 29.

29.

Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes.

Vose JM, Levit LA, Hurley P, Lee C, Thompson MA, Stewart T, Hofacker J, Bruinooge SS, Hayes DF.

J Clin Oncol. 2016 Nov 1;34(31):3796-3802. doi: 10.1200/JCO.2016.69.6781. No abstract available.

PMID:
27601549
30.

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P.

J Natl Compr Canc Netw. 2016 Sep;14(9):1067-79.

PMID:
27587620
31.

Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.

Landsburg DJ, Falkiewicz MK, Petrich AM, Chu BA, Behdad A, Li S, Medeiros LJ, Cassaday RD, Reddy NM, Bast MA, Vose JM, Kruczek KR, Smith SE, Patel P, Hernandez-Ilizaliturri F, Karmali R, Rajguru S, Yang DT, Maly JJ, Blum KA, Zhao W, Vanslambrouck C, Nabhan C.

Br J Haematol. 2016 Nov;175(4):631-640. doi: 10.1111/bjh.14282. Epub 2016 Jul 29.

32.

2016 ASCO Presidential Address: "Collective Wisdom: The Future of Patient-Centered Care and Research".

Vose JM.

J Clin Oncol. 2016 Sep 1;34(25):2945-9. doi: 10.1200/JCO.2016.68.9786. Epub 2016 Jul 11. No abstract available.

PMID:
27400938
33.

Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.

Bhatt VR, Giri S, Verma V, Manandhar S, Pathak R, Bociek RG, Vose JM, Armitage JO.

Clin Lymphoma Myeloma Leuk. 2016 Jul;16(7):373-8. doi: 10.1016/j.clml.2016.04.015. Epub 2016 May 4.

PMID:
27349764
34.

Forest drought as an emerging research priority.

Clark JS, Vose JM, Luce CH.

Glob Chang Biol. 2016 Jul;22(7):2317. doi: 10.1111/gcb.13252. No abstract available.

PMID:
27282321
35.

Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, Hoverman JR, Langdon R, Lyman GH, Meropol NJ, Mulvey T, Newcomer L, Peppercorn J, Polite B, Raghavan D, Rossi G, Saltz L, Schrag D, Smith TJ, Yu PP, Hudis CA, Vose JM, Schilsky RL.

J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31. No abstract available.

PMID:
27247218
36.

Secondary acute myeloid leukemia in survivors of Hodgkin lymphoma.

Bhatt VR, Giri S, Verma V, Dahal S, Shah BK, Pathak R, Bociek RG, Vose JM, Armitage JO.

Future Oncol. 2016 Jul;12(13):1565-75. doi: 10.2217/fon-2016-0048. Epub 2016 Apr 15.

PMID:
27079926
37.

Diffuse Large B-Cell Lymphoma Version 1.2016.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2016 Feb;14(2):196-231.

PMID:
26850490
38.

Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.

Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, Hung S, Rosenwald A, Gascoyne R, Fu K, Greiner TC, Weisenburger DD, Vose JM, Staudt LM, Xiao W, Borgstahl GE, Davis S, Steidl C, McKeithan T, Iqbal J, Chan WC.

Leukemia. 2016 May;30(5):1062-70. doi: 10.1038/leu.2015.357. Epub 2015 Dec 31.

39.

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.

Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, Pinter-Brown LC, Smith SM, Shustov AR, Savage KJ, Vose JM.

Br J Haematol. 2016 Feb;172(4):535-44. doi: 10.1111/bjh.13855. Epub 2015 Dec 2.

40.

A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.

Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL.

Clin Cancer Res. 2016 Mar 1;22(5):1059-66. doi: 10.1158/1078-0432.CCR-15-0624. Epub 2015 Oct 19.

41.

Drought limitations to leaf-level gas exchange: results from a model linking stomatal optimization and cohesion-tension theory.

Novick KA, Miniat CF, Vose JM.

Plant Cell Environ. 2016 Mar;39(3):583-96. doi: 10.1111/pce.12657. Epub 2016 Jan 8.

42.

The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project.

Bellei M, Nabhan C, Pesce EA, Conte L, Vose JM, Foss F, Federico M.

Curr Hematol Malig Rep. 2015 Dec;10(4):448-55. doi: 10.1007/s11899-015-0291-0. Review.

PMID:
26449717
43.

To Surveil or Not to Surveil.

Armitage JO, Vose JM.

J Clin Oncol. 2015 Dec 1;33(34):3983-4. doi: 10.1200/JCO.2015.63.5946. Epub 2015 Oct 5. No abstract available.

PMID:
26438116
44.

Genomic signatures in B-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

Iqbal J, Naushad H, Bi C, Yu J, Bouska A, Rohr J, Chao W, Fu K, Chan WC, Vose JM.

Blood Rev. 2016 Mar;30(2):73-88. doi: 10.1016/j.blre.2015.08.002. Epub 2015 Aug 18. Review.

PMID:
26432520
45.

Forest biogeochemistry in response to drought.

Schlesinger WH, Dietze MC, Jackson RB, Phillips RP, Rhoades CC, Rustad LE, Vose JM.

Glob Chang Biol. 2016 Jul;22(7):2318-28. doi: 10.1111/gcb.13105. Epub 2015 Nov 18.

PMID:
26403995
46.
47.

Building Bridges for Collective Wisdom.

Yu PP, Vose JM.

J Glob Oncol. 2015 Sep 23;1(1):1-2. doi: 10.1200/JGO.2015.000737. eCollection 2015 Oct. No abstract available.

48.

Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience.

Bhatt VR, Loberiza FR Jr, Smith LM, Armitage JO, Greiner TC, Bast M, Lunning MA, Bierman PJ, Vose JM, Bociek RG.

Leuk Lymphoma. 2016;57(6):1327-34. doi: 10.3109/10428194.2015.1094801. Epub 2015 Oct 16.

PMID:
26377137
49.

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.

Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA.

Br J Haematol. 2015 Dec;171(5):726-35. doi: 10.1111/bjh.13659. Epub 2015 Sep 11.

50.

An interview with Julie Vose: where is oncology heading?

Vose JM, Westcott G.

Future Oncol. 2015;11(20):2803-5. doi: 10.2217/fon.15.215. Epub 2015 Sep 11.

Supplemental Content

Support Center